Surmodics, Inc. (SRDX) Stock

SRDX logo

Surmodics, Inc.

SRDX
Healthcare

Company profile

Surmodics reported revenue of $126.08 million for fiscal year 2024, down 4.9% from fiscal year 2023. In Q3 2025 (the quarter ended June 30, 2025) revenue was $29.57 million, down 2.6% from a year before. Its largest business segment, Medical Device, brought in 77% of segment revenue in fiscal year 2024; United States was the largest region with 83%. In Q3 2025 it reported a net loss of $5.32 million, against a net loss of $7.55 million a year earlier. Our analysis of its filings shows revenue growing from $99.95 million in fiscal year 2022 to $126.08 million in fiscal year 2024, 12.3% a year on average.

What stands out

  • It reported a net loss in each of its last 3 fiscal years, after a profit of $4.24 million in fiscal year 2021; the loss widened from $1.54 million in fiscal year 2023 to $11.54 million in fiscal year 2024.

Figures from company filings; latest fiscal year ended September 30, 2024.

Largest shareholders

  • BlackRock Advisors LLC7.71%
  • AllianceBernstein LP5.95%
  • Vanguard Fiduciary Trust Co.5.67%
  • Soleus Capital Management LP5.52%
  • Trium Capital LLP5.01%

Share of the company, as of November 8, 2025

How much revenue does Surmodics make?

Surmodics reported $126.08 million in revenue for fiscal year 2024, down 4.9% from $132.58 million in fiscal year 2023. In Q3 2025 revenue was $29.57 million.

What is Surmodics's largest business segment?

Medical Device, with $97.51 million or 77% of segment revenue in fiscal year 2024. Next: In Vitro Diagnostics (23%).

Where does Surmodics make most of its revenue?

United States: 83% of revenue by region in fiscal year 2024, followed by Foreign (17%).

What companies are similar to Surmodics?

Listed companies of a similar size in the same industry (healthcare equipment manufacturing contractors) include Integer Holdings Corporation (ITGR), Varex Imaging Corporation (VREX), Pro-Dex, Inc. (PDEX), Nutriband Inc. (NTRB).

Has Surmodics made a profit in recent years?

Net income by fiscal year: FY2020, $1.12 million; FY2021, $4.24 million; FY2022, a loss of $27.27 million; FY2023, a loss of $1.54 million; FY2024, a loss of $11.54 million. It reported a net loss in 3 of these 5 years.

Company Information

SectorHealthcare
IndustryHealthcare Equipment Manufacturing Contractors
Founded1979
IPO DateMar 4, 1998
IPO StatusPublic
ExchangeNasdaqGS
TimezoneAmerica/New_York (EST)
Disclaimer: This analysis is for informational and educational purposes only and does not constitute financial, investment, tax, or legal advice. Data may be incomplete, delayed, or contain inaccuracies. Consult with a qualified financial advisor before making any investment decisions.

Data as of .

How to cite: DataPorium, “Surmodics, Inc. (SRDX)”, data as of Nov 8, 2025, https://dataporium.tech/stocks/SRDX

LinkedInLinkedInXXYouTubeYouTube